© 2020 MJH Life Sciences and AJMC. All rights reserved.
© 2020 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
October 30, 2020
The study offers the first de novo cost-effectiveness model of these patients in the United States, according to the researchers.
October 29, 2020
Findings from a retrospective analysis support the use of splenectomy for patients with progressive disease and large splenomegaly.
October 25, 2020
Researchers are urging caution when it comes to the use of adenovirus type-5 (Ad5) vectored vaccines for COVID-19.
October 24, 2020
Their study outlines several treatments being investigated for the treatment of patients with myelofibrosis and other myeloproliferative neoplasms, generally after they have become resistant or intolerant to Janus kinase inhibition.